MADD Canada Brings New School Program to Newfoundland and Labrador Students

BAY ROBERTS, Newfoundland and Labrador, Oct. 16, 2024 (GLOBE NEWSWIRE) — MADD Canada is proud to announce the provincial launch of its 2024-2025 School Program which educates youth about the risks and consequences of impaired driving. MADD Canada’s School Program One Last Dance will be delivered to Newfoundland and Labrador students in Grades 7-12, with […]

Medallion Financial Corp. to Report 2024 Third Quarter Results on Tuesday, October 29, 2024

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) — Medallion Financial Corp. (NASDAQ: MFIN, the “Company”), a specialty finance company that originates and services loans in various consumer and commercial industries, as well as loan products and services offered through fintech strategic partners, announced today that it will report its results for the quarter ended September

VedTechBio(R) Launches RxAgentAI(TM) – an Artificial Intelligence and Machine Learning Platform, catering to the decision making and strategic needs of stakeholders in the life sciences industry AND VedTechBio(R) Announces a Drug Discovery Collaboration with RenaissThera(R)

BENGALURU, India, Oct. 16, 2024 (GLOBE NEWSWIRE) — VedTechBio Research Pvt. Ltd. (VedTechBio), a pioneering Biopharma-Technology enterprise committed to enhancing human well-being and enriching quality of life by expediting drug discovery and development, today announced the launch of RxAgentAI, its AI- and ML-driven technology platform. VedTechBio is using RxAgentAI in advancing the industry norm of

Norsk Hydro: Status share buyback program

Please see below information about transactions made under the share buyback program for Norsk Hydro ASA. Announcement date of the share buyback program: September 11, 2024 End date of the share buyback program: February 28, 2025 Overview of transactions: Date Aggregated daily volume (number of Shares) Weighted average share price per day (NOK) Total daily

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading scientists, industry experts, investors, and regulatory authorities at the GenScript Biotech Global Forum. This series of conferences aims to

Economist Mazzucato warns of risks from uncontrolled innovation at TCI Network Conference

Italian-American economistMariana Mazzucato has warned in Mexico about the risks of innovation driven by policies that exacerbate inequality, noting that some of the “stupidest fiscal policies have been implemented in the name of entrepreneurship.” During her speech at the 27thTCI Network Conference, held in Chihuahua, northern Mexico, Mazzucato pointed out that the current global financial

Save the Storks and Options for Her Teams Meet with Princeton University Students on Campus

Vice President Kamala Harris toured rallies in the past month with the ‘Reproductive Freedom’ bus, and a widely publicized abortion van offered free abortions at the Democratic National Convention in Chicago. In light of this, Princeton University surprised Save the Storks and Options for Her by inviting them to bring a life-affirming mobile medical clinic

Airtel Business and Vonage partner to launch cutting-edge business communications application

New communications application includes multi-channel capabilities, real-time monitoring and data loss prevention to help enterprises in India enhance their stakeholder communications Airtel Business,the B2B arm of Bharti Airtel Ì one of India’s leading telecommunications service providers Ì and Vonage,a global leader in cloud communications that helps businesses accelerate their digital transformation and a part of

Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication

WOBURN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) — Neurogastrx, Inc. today announced positive topline results from a new study of NG101 (metopimazine mesylate) showing significant reduction of nausea and vomiting side effects caused by a glucagon-like peptide 1 (GLP-1) agonist medication. NG101 is an oral, peripherally restricted dopamine D2 receptor antagonist. “The randomized, double-blind, placebo-controlled

Scroll to Top